The impact of drug resistance on Mycobacterium tuberculosis physiology: What can we learn from rifampicin?

Emerging Microbes and Infections

Volumn 3, Issue , 2014, Pages

  Koch, Anastasia ^a   Mizrahi, Valerie ^a   Warner, Digby F ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Epistasis; Fitness cost; RNA polymerase; rpoB; TB

Indexed keywords

RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIAL PHENOMENA AND FUNCTIONS; CELL FUNCTION; CELL METABOLISM; CELL STRESS; COMPETITIVE BEHAVIOR; DRUG COST; EPIDEMIOLOGICAL DATA; EPISTASIS; HOST PATHOGEN INTERACTION; HUMAN; IN VITRO STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REPRODUCTIVE FITNESS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84896281808     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2014.17     Document Type: Review

References (151)

1. Cars O, Hogberg LD, Murray M et al. Meeting the challenge of antibiotic resistance. BMJ 2008; 337: a1438.
2. Martinez JL, Fajardo A, Garmendia L et al. A global view of antibiotic resistance.FEMS Microbiol Rev 2009; 33: 44-65.
3. World Health Organization. Global tuberculosis report 2013. Geneva: WHO, 2013. Available at http://www.who.int/tb/publications/globalreport/en/index.html (accessed December 2013).
4. Pooran A, Pieterson E, DavidsM, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS ONE 2013; 8: e54587.
5. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science 2009; 325: 1089-1093.
6. Gandhi NR, Nunn P, Dheda K et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830- 1843.
7. Colijn C, Cohen T, Ganesh A, Murray M. Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PLoS ONE 2011; 6: e18327.
8. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004; 10: 1111-1116. (Pubitemid 39424873)
9. Muller B, Borrell S, Rose G, Gagneux S. The heterogeneous evolution of multidrugresistant Mycobacterium tuberculosis. Trends Genet 2012; 29: 160-169.
10. Farhat MR, Shapiro BJ, Kieser K et al. Genomic analysis identifies targets of convergent positive selection in drug resistant Mycobacterium tuberculosis. Nat Genet 2013; 45: 1183-1189.
11. Zhang H, Li D, Zhao L et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet 2013; 45: 1255-1260.
12. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med 2009; 6: e2.
13. Casali N, Nikolayevskyy V, Balabanova Y et al. Microevolution of extensively drugresistant tuberculosis in Russia. Genome Res 2012; 22: 735-745.
14. Ioerger TR, Feng Y, Chen X et al. The non-clonality of drug resistance in Beijinggenotype isolates of Mycobacterium tuberculosis from the Western Cape of South Africa. BMC Genomics 2010; 11: 670.
15. Sun G, Luo T, Yang C et al. Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis 2012; 206: 1724-1733.
16. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8: 260-271.
17. Borukhov S, Nudler E. RNA polymerase: the vehicle of transcription. Trends Microbiol 2008; 16: 126-134.
18. Campbell EA, Korzheva N, Mustaev A et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001; 104: 901-912. (Pubitemid 32289282)
19. Comas I, Coscolla M, Luo T et al. Out-of-Africa migration and Neolithic co-expansion of tuberculosis with modern humans. Nat Genet 2013; 45: 1176-1182.
20. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4: 796-806.
21. Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010; 23: 14-34.
22. Lipsitch M, Levin BR. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 1997; 41: 363-373. (Pubitemid 27111032)
23. Xie Z, Siddiqi N, Rubin EJ. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2005; 49: 4778-4780. (Pubitemid 41552617)
24. Piccaro G, Giannoni F, Filippini P, Mustazzolu A, Fattorini L. Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions. Antimicrob Agents Chemother 2013; 57: 1428-1433.
25. Sala C, Dhar N, Hartkoorn RC et al. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010; 54: 4150-4158.
26. Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS Med 2007; 4: e120.
27. Barry CE, 3rd, BoshoffHI, Dartois V et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7: 845-855.
28. Rittershaus ES, Baek SH, Sassetti CM. The normalcy of dormancy: common themes in microbial quiescence. Cell Host Microbe 2013; 13: 643-651.
29. Donald PR, van Helden PD. The global burden of tuberculosis-combating drug resistance in difficult times. N Engl J Med 2009; 360: 2393-2395.
30. Zhang G, Campbell EA, Minakhin L,Richter C, Severinov K, Darst SA. Crystal structure of Thermus aquaticus core RNA polymerase at 3.3 A resolution. Cell 1999; 98: 811-824.
31. Borukhov S, Nudler E. RNA polymerase holoenzyme: structure, function and biological implications. Curr Opin Microbiol 2003; 6: 93-100. (Pubitemid 36628650)
32. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79: 3-29. (Pubitemid 29050434)
33. Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol 1988; 202: 45-58.
34. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. Molecular genetics of mycobacteria. Washington, DC: ASM Press, 2000.
35. Heep M, Brandstatter B, Rieger U et al. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 2001; 39: 107-110. (Pubitemid 32059577)
36. Heep M, Odenbreit S, Beck D et al. Mutations at four distinct regions of the rpoB gene can reduce the susceptibility of Helicobacter pylori to rifamycins. Antimicrob Agents Chemother 2000; 44: 1713-1715. (Pubitemid 30340823)
37. Telenti A, Imboden P, Marchesi F et al. Detection of rifampicin- resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-650. (Pubitemid 23083244)
38. Zhou YN, Jin DJ. The rpoB mutants destabilizing initiation complexes at stringently controlled promoters behave like "stringent" RNA polymerases in Escherichia coli. Proc Natl Acad Sci USA 1998; 95: 2908-2913. (Pubitemid 128617610)
39. Hosaka T, Ohnishi-Kameyama M, Muramatsu H et al. Antibacterial discovery in actinomycetes strains with mutations in RNA polymerase or ribosomal protein S12. Nat Biotechnol 2009; 27: 462-464.
40. Singer M, Jin DJ, Walter WA, Gross CA. Genetic evidence for the interaction between cluster I and cluster III rifampicin resistant mutations. J Mol Biol 1993; 231: 1-5. (Pubitemid 23186592)
41. Jin DJ, Gross CA. Characterization of the pleiotropic phenotypes of rifampin-resistant rpoB mutants of Escherichia coli. J Bacteriol 1989; 171: 5229-5231. (Pubitemid 19209090)
42. Jin DJ, Gross CA. RpoB8, a rifampicin-resistant termination-proficient RNA polymerase, has an increased Km for purine nucleotides during transcription elongation. J Biol Chem 1991; 266: 14478-14485. (Pubitemid 21907528)
43. Jin DJ, Walter WA, Gross CA. Characterization of the termination phenotypes of rifampicin-resistant mutants. J Mol Biol 1988; 202: 245-253.
44. Landick R, Stewart J, Lee DN. Amino acid changes in conserved regions of the betasubunit of Escherichia coli RNA polymerase alter transcription pausing and termination. Genes Dev 1990; 4: 1623-1636.
45. Yanofsky C, Horn V. Rifampin resistance mutations that alter the efficiency of transcription termination at the tryptophan operon attenuator. J Bacteriol 1981; 145: 1334-1341. (Pubitemid 11097353)
46. Ingham CJ, Furneaux PA. Mutations in the ss subunit of the Bacillus subtilis RNA polymerase that confer both rifampicin resistance and hypersensitivity to NusG. Microbiology 2000; 146: 3041-3049. (Pubitemid 32007660)
47. Trautinger BW, Lloyd RG. Modulation of DNA repair by mutations flanking the DNA channel through RNA polymerase. EMBO J 2002; 21: 6944-6953. (Pubitemid 36014566)
48. Ganesan AK, Smith AJ, Savery NJ, Zamos P, Hanawalt PC. Transcription coupled nucleotide excision repair in Escherichia coli can be affected by changing the arginine at position 529 of the beta subunit of RNA polymerase. DNA Repair (Amst) 2007; 6: 1434-1440. (Pubitemid 47385395)
49. Baharoglu Z, Lestini R, Duigou S, Michel B. RNA polymerase mutations that facilitate replication progression in the rep uvrD recF mutant lacking two accessory replicative helicases. Mol Microbiol 2010; 77: 324-336.
50. Dabbs ER. New tool for studying interactions of components of ribonucleic acid polymerase: rifampin-dependent mutants. J Bacteriol 1979; 139: 1072-1074. (Pubitemid 10226589)
51. Zhong M, Wang Y, Sun C, Yin H, Wang A, Lou L. [Growth of rifampin-dependent Mycobacterium tuberculosis in conditions without rifampin]. Zhonghua Jie He He Hu Xi Za Zhi 2002; 25: 588-590. Chinese.
52. Zhong M, Zhang X, Wang Y et al. An interesting case of rifampicin-dependent/ -enhanced multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2010; 14: 40-44.
53. Honore N, Marchal G, Cole ST. Novel mutation in 16S rRNA associated with streptomycin dependence in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 769-770.
54. Mokrousov I. Multiple rpoB mutants of Mycobacterium tuberculosis and second-order selection. Emerg Infect Dis 2004; 10: 1337-1338. (Pubitemid 38890958)
55. Lindahl T. Instability and decay of the primary structure of DNA. Nature 1993; 362: 709-715. (Pubitemid 23125973)
56. Warner DF. The role of DNA repair in M. tuberculosis pathogenesis. Drug Discov Today 2010; 7: e5-e11.
57. Ehrt S, Schnappinger D. Mycobacterial survival strategies in the phagosome: defence against host stresses. Cell Microbiol 2009; 11: 1170-1178.
58. O'Sullivan DM, McHugh TD, Gillespie SH. Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution? J Antimicrob Chemother 2005; 55: 674-679. (Pubitemid 40691845)
59. Ford CB, Shah RR, Maeda MK et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 2013; 45: 784-790.
60. Siu GK, Zhang Y, Lau TC et al. Mutations outside the rifampicin resistancedetermining region associated with rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2011; 66: 730-733.
61. Van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010; 14: 131-140.
62. Lindsey HA, Gallie J, Taylor S, Kerr B. Evolutionary rescue from extinction is contingent on a lower rate of environmental change. Nature 2013; 494: 463-467.
63. Jenkins C, Bacon J, Allnutt J et al. Enhanced heterogeneity of rpoB in Mycobacterium tuberculosis found at low pH. J Antimicrob Chemother 2009; 63: 1118-1120.
64. Mariam DH, Mengistu Y, Hoffner SE, AndersonDI. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48: 1289-1294. (Pubitemid 38405483)
65. Andersson DI. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 2006; 9: 461-465. (Pubitemid 44397630)
66. Gagneux S, Burgos MV, DeRiemer K et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLos Pathog 2006; 2: e61.
67. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312: 1944-1946. (Pubitemid 43993719)
68. Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogenous fitness. Nat Med 2004; 10: 1117-1121. (Pubitemid 39424874)
69. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drugresistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1456-1466.
70. Brandis G, Hughes D. Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates. J Antimicrob Chemother 2013; 68: 2493-2497.
71. Billington OJ, McHugh TD, Gillespie SH. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43: 1866-1869. (Pubitemid 29395177)
72. Davies AP, Billington OJ, Bannister BA, Weir WR, McHugh TD, Gillespie SH. Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment. J Infect 2000; 41: 184-187.
73. Gillespie SH, Billington OJ, Breathnach A, McHugh TD. Multiple drug-resistant Mycobacterium tuberculosis: evidence for changing fitness following passage through human hosts. Microb Drug Resist 2002; 8: 273-279. (Pubitemid 36043693)
74. Kolter R, Siegele DA, Tormo A. The stationary phase of the bacterial life cycle. Annu Rev Microbiol 1993; 47: 855-874. (Pubitemid 23302955)
75. Wrande M, Roth JR, Hughes D. Accumulation of mutants in "aging" bacterial colonies is due to growth under selection, not stress-induced mutagenesis. Proc Natl Acad Sci USA 2008; 105: 11863-11868.
76. Barczak AK, Domenech P, Boshoff HI et al. In vivo phenotypic dominance in mouse mixed infections with Mycobacterium tuberculosis clinical isolates. J Infect Dis 2005; 192: 600-606. (Pubitemid 41099308)
77. Subbian S, Bandyopadhyay N, Tsenova L et al. Early innate immunity determines outcome of Mycobacterium tuberculosis pulmonary infection in rabbits. Cell Commun Signal 2013; 11: 60.
78. Safi H, Lingaraju S, Amin A et al. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-b-D-arabinose biosynthetic and utilization pathway genes. Nat Genet 2013; 45: 1190-1197.
79. Comas I, Borrell S, Roetzer A et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 2012; 44: 106-110.
80. Firdessa R, Berg S, Hailu E et al. Mycobacterial lineages causing pulmonary and extrapulmonary tuberculosis, Ethiopia. Emerg Infect Dis 2013; 19: 460-463.
81. de Vos M, Muller B, Borrell S et al. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother 2013; 57: 827-832.
82. Brandis G, Wrande M, Liljas L, Hughes D. Fitness-compensatory mutations in rifampicin-resistant RNA polymerase. Mol Microbiol 2012; 85: 142-151.
83. Cordell HJ. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet 2002; 11: 2463-2468. (Pubitemid 35174710)
84. Trindade S, Sousa A, Xavier KB, Dionisio F, Ferreira MG, Gordo I. Positive epistasis drives the acquisition of multidrug resistance. PLoS Genet 2009; 5: e1000578.
85. Baker S, Duy PT, Nga TV et al. Fitness benefits in fluoroquinolone- resistant Salmonella Typhi in the absence of antimicrobial pressure. Elife 2013; 2: e01229.
86. Hall AR, James IC, Maclean C. The fitness cost of rifampicin resistance in Pseudomonas aeruginosa depends on demand for RNA polymerase. Genetics 2011; 187: 817-822.
87. Bergval I, Kwok B, Schuitema A et al. Pre-existing isoniazid resistance, but not the genotype of Mycobacterium tuberculosis drives rifampicin resistance codon preference in vitro. PLoS ONE 2012; 7: e29108.
88. Hazbon MH, Brimacombe M, Bobadilla del ValleMet al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006; 50: 2640-2649. (Pubitemid 44198682)
89. van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacteriumtuberculosis in the Netherlands. J Infect Dis 2000; 182: 1788-1790.
90. Borrell S, Teo Y, Giardina F et al. Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. EMPH 2013; 2013: 65-74.
91. Rovinskiy N, Agbleke AA, Chesnokova O, Pang Z, Higgins NP. Rates of gyrase supercoiling and transcription elongation control supercoil density in a bacterial chromosome. PLoS Genet 2012; 8: e1002845.
92. Gagneux S, DeRiemer K, Van T et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006; 103: 2869-2873.
93. Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson DI, Bottger EC. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 2010; 77: 830-840.
94. Saunders NJ, Trivedi UH, Thomson ML, Doig C, Laurenson IF, Blaxter ML. Deep resequencing of serial sputum isolates of Mycobacterium tuberculosis during therapeutic failure due to poor compliance reveals stepwise mutation of key resistance genes on an otherwise stable genetic background. J Infect 2011; 62: 212-217.
95. Drobniewski FA, Caws M, Gibson A, Young D. Modern laboratory diagnosis of tuberculosis. Lancet Infect Dis 2003; 3: 141-147. (Pubitemid 36278123)
96. Strauss O, Warren R, Jordaan A et al. Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. J Clin Microbiol 2008; 46: 1514-1516. (Pubitemid 351563605)
97. Malhotra S, Cook VJ, Wolfe JN, Tang P, Elwood K, Sharma MK. A mutation in Mycobacterium tuberculosis rpoB gene confers rifampin resistance in three HIV-TB cases. Tuberculosis (Edinb) 2010; 90: 152-157.
98. Motiwala AS, Dai Y, Jones-Lopez EC et al. Mutations in extensively drug-resistant Mycobacterium tuberculosis that do not code for known drug-resistance mechanisms. J Infect Dis 2010; 201: 881-888.
99. Lane WJ, Darst SA. Molecular evolution of multisubunit RNA polymerases: sequence analysis. J Mol Biol 2010; 395: 671-685.
100. Lane WJ, Darst SA. Molecular evolution of multisubunit RNA polymerases: structural analysis. J Mol Biol 2010; 395: 686-704.
101. Nicholson WL, Maughan H. The spectrum of spontaneous rifampin resistance mutations in the rpoB gene of Bacillus subtilis 168 spores differs from that of vegetative cells and resembles that of Mycobacterium tuberculosis. J Bacteriol 2002; 184: 4936-4940.
102. Maughan H, Galeano B, Nicholson WL. Novel rpoB mutations conferring rifampin resistance on Bacillus subtilis: global effects on growth, competence, sporulation, and germination. J Bacteriol 2004; 186: 2481-2486. (Pubitemid 38451852)
103. Perkins AE, Nicholson WL. Uncovering new metabolic capabilities of Bacillus subtilis using phenotype profiling of rifampin-resistant rpoB mutants. J Bacteriol 2008; 190: 807-814. (Pubitemid 351170923)
104. Xu J, Tozawa Y, Lai C, Hayashi H, Ochi K. A rifampicin resistance mutation in the rpoB gene confers ppGpp-independent antibiotic production in Streptomyces coelicolor A3(2). Mol Genet Genomics 2002; 268: 179-189. (Pubitemid 35471769)
105. Hu H, Zhang Q, Ochi K. Activation of antibiotic biosynthesis by specified mutations in the rpoB gene (encoding the RNA polymerase beta subunit) of Streptomyces lividans. J Bacteriol 2002; 184: 3984-3991. (Pubitemid 34705457)
106. Inaoka T, Takahashi K, Yada H, Yoshida M, Ochi K. RNA polymerase mutation activates the production of a dormant antibiotic 3,39-neotrehalosadiamine via an autoinduction mechanism in Bacillus subtilis. J Biol Chem 2004; 279: 3885-3892. (Pubitemid 38140634)
107. Murphy H, Cashel M. Isolation of RNA polymerase suppressors of a (p) ppGpp deficiency. Methods Enzymol 2003; 371: 596-601. (Pubitemid 37542760)
108. Applebee MK, Herrgard MJ, Palsson BO. Impact of individual mutations on increased fitness in adaptively evolved strains of Escherichia coli. J Bacteriol 2008; 190: 5087-5094. (Pubitemid 351991076)
109. Conrad TM, Frazier M, Joyce AR et al. RNA polymerase mutants found through adaptive evolution reprogram Escherichia coli for optimal growth in minimal media. Proc Natl Acad Sci USA 2010; 107: 20500-20505.
110. Herring CD, Raghunathan A, Honisch C et al. Comparative genome sequencing of Escherichia coli allows observation of bacterial evolution on a laboratory timescale. Nat Genet 2006; 38: 1406-1412. (Pubitemid 44837562)
111. Rodriguez-Verdugo A, Gaut BS, Tenaillon O. Evolution of Escherichia coli rifampicin resistance in an antibiotic-free environment during thermal stress. BMC Evol Biol 2013; 13: 50.
112. Louw GE, Warren RM, Gey van Pittius NC et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 2011; 184: 269-276.
113. Bisson GP, Mehaffy C, Broeckling C et al. Upregulation of the phthiocerol dimycocerosate biosynthetic pathway by rifampin-resistant, rpoB mutant Mycobacterium tuberculosis. J Bacteriol 2012; 194: 6441-6452.
114. du Preez I, Loots D. Altered fatty acid metabolism due to rifampicin-resistance conferring mutations in the rpoB gene of Mycobacterium tuberculosis: mapping the potential of pharmaco-metabolomics for global health and personalized medicine. Omics, 2012, 16 596-603.
115. Bergval IL, Klatser PR, Schuitema AR, Oskam L, Anthony RM. Specific mutations in the Mycobacterium tuberculosis rpoB gene are associated with increased dnaE2 expression. FEMS Microbiol Lett 2007; 275: 338-343. (Pubitemid 47437870)
116. Abadi FJ, Carter PE, Cash P, Pennington TH. Rifampin resistance in Neisseria meningitidis due to alterations in membrane permeability. Antimicrob Agents Chemother 1996; 40: 646-651. (Pubitemid 26071531)
117. Tala A, Wang G, Zemanova M, Okamoto S, Ochi K, Alifano P. Activation of dormant bacterial genes by Nonomuraea sp. strain ATCC 39727 mutant-type RNA polymerase. J Bacteriol 2009; 191: 805-814.
118. Vigliotta G, Tredici SM, Damiano F et al. Natural merodiploidy involving duplicated rpoB alleles affects secondary metabolism in a producer actinomycete. Mol Microbiol 2005; 55: 396-412. (Pubitemid 40179376)
119. Ishikawa J, Chiba K, Kurita H, Satoh H. Contribution of rpoB2 RNA polymerase beta subunit gene to rifampin resistance in Nocardia species. Antimicrob Agents Chemother 2006; 50: 1342-1346.
120. Yu J, Wu J, Francis KP, Purchio TF, Kadurugamuwa JL. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother 2005; 55: 528-534. (Pubitemid 40542595)
121. Cui L, Isii T, Fukuda M et al. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54: 5222-5233.
122. Watanabe Y, Cui L, Katayama Y, Kozue K, Hiramatsu K. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J Clin Microbiol 2011; 49: 2680-2684.
123. Ochi K. Metabolic initiation of differentiation and secondary metabolism by Streptomyces griseus: significance of the stringent response (ppGpp) and GTP content in relation to A factor. J Bacteriol 1987; 169: 3608-3616. (Pubitemid 17160317)
124. Artsimovitch I, Patlan V, Sekine S et al. Structural basis for transcription regulation by alarmone ppGpp. Cell 2004; 117: 299-310. (Pubitemid 38534537)
125. Koskiniemi S, Pranting M, Gullberg E, Nasvall J, Andersson DI. Activation of cryptic aminoglycoside resistance in Salmonella enterica. Mol Microbiol 2011; 80: 1464-1478.
126. Primm TP, Andersen SJ, Mizrahi V, Avarbock D, Rubin H, BarryCE 3rd. The stringent response of Mycobacterium tuberculosis is required for long-term survival. J Bacteriol 2000; 182: 4889-4898. (Pubitemid 30641814)
127. Dahl JL, Kraus CN, Boshoff HI et al. The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci USA 2003; 100: 10026-10031. (Pubitemid 37087062)
128. Jackson M, Stadthagen G, Gicquel B. Long-chain multiple methyl-branched fatty acid-containing lipids of Mycobacterium tuberculosis: biosynthesis, transport, regulation and biological activities. Tuberculosis (Edinb) 2007; 87: 78-86. (Pubitemid 46217257)
129. Matsuo M, Hishinuma T, Katayama Y, Cui L, Kapi M, Hiramatsu K. Mutation of RNA polymerase b subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. Antimicrob Agents Chemother 2011; 55: 4188-4195.
130. Ehrt S, Rhee K. Mycobacterium tuberculosis metabolism and host interaction: mysteries and paradoxes. Curr Top Microbiol Immunol 2013; 374: 163-188.
131. Russell DG. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunol Rev 2011; 240: 252-268.
132. Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012; 12: 581-591.
133. Lee J, Song C, Kim C et al. Profiles of IFN-c and its regulatory cytokines (IL-12, IL-18 and IL-10) in peripheral blood mononuclear cells from patients with multidrugresistant tuberculosis. Clin Exp Immunol 2002; 128: 516-524. (Pubitemid 34639315)
134. Prasad TS, Verma R, Kumar S et al. Proteomic analysis of purified protein derivative of Mycobacterium tuberculosis. Clin Proteomics 2013; 10: 8.
135. van Pinxteren LA, Ravn P, Agger EM, Pollock J, Andersen P. Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin Diagn Lab Immunol 2000; 7: 155-160. (Pubitemid 30132105)
136. Fortes A, Pereira K, Antas PR et al. Detection of in vitro interferon-gamma and serum tumour necrosis factor-alpha in multidrug-resistant tuberculosis patients. Clin Exp Immunol 2005; 141: 541-548. (Pubitemid 41075879)
137. de Araujo-Filho JA, Vasconcelos AC Jr, Martins de Sousa E, Kipnis A, Ribeiro E, Junqueira-Kipnis AP. Cellular responses to MPT-51, GlcB and ESAT-6 among MDR-TB and active tuberculosis patients in Brazil. Tuberculosis (Edinb) 2008; 88: 474-481.
138. Castro AZ, Diaz-Bardalez BM, Oliveira EC et al. Abnormal production of transforming growth factor b and interferon c by peripheral blood cells of patients with multidrugresistant pulmonary tuberculosis in Brazil. J Infect 2005; 51: 318-324. (Pubitemid 41683873)
139. Wu YE, Peng WG, Cai YM et al. Decrease in CD41 CD251 FoxP31 Treg cells after pulmonary resection in the treatment of cavity multidrug-resistant tuberculosis. Int J Infect Dis 2010; 14: e815.
140. Karunakaran P, Davies J. Genetic antagonism and hypermutability in Mycobacterium smegmatis. J Bacteriol 2000; 182: 3331-3335. (Pubitemid 30341592)
141. Bjedov I, Tenaillon O, Gerard B et al. Stress-induced mutagenesis in bacteria. Science 2003; 300: 1404-1409. (Pubitemid 36638154)
142. Cairns J, Overbaugh J, Miller S. The origin of mutants. Nature 1988; 335: 142-145.
143. Rosenberg SM, Hastings PJ. Adaptive point mutation and adaptive amplification pathways in the Escherichia coli Lac system: stress responses producing genetic change. J Bacteriol 2004; 186: 4838-4843. (Pubitemid 38970807)
144. Katz S, Hershberg R. Elevated mutagenesis does not explain the increased frequency of antibiotic resistant mutants in starved aging colonies. PLOS Genet 2013; 9: e1003968.
145. Dragosits M, Mozhayskiy V, Quinones-Soto S, Park J, Tagkopoulos I. Evolutionary potential, cross-stress behavior and the genetic basis of acquired stress resistance in Escherichia coli. Mol Syst Biol 2013; 9: 643.
146. Webber MA, Ricci V, Whitehead R et al. Clinically relevant mutant DNA gyrase alters supercoiling, changes the transcriptome, and confers multidrug resistance. MBio 2013; 4: e00273-13.
147. Quan S, Venter H, Dabbs ER. Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic. Antimicrob Agents Chemother 1997; 41: 2456-2460. (Pubitemid 27467556)
148. Adams KN, Takaki K, Connolly LE et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 2011; 145: 39-53.
149. Fange D, Nilsson K, Tenson T, Ehrenberg M. Drug efflux pump deficiency and drug target resistance masking in growing bacteria. Proc Natl Acad Sci USA 2009; 106: 8215-8220.
150. Bhat J, Narayan A, Venkatraman J, Chatterji M. LC-MS based assay to measure intracellular compound levels in Mycobacterium smegmatis: Linking compound levels to cellular potency. J Microbiol Methods 2013; 94: 152-158.
151. Wood R, Lawn SD, Johnstone-Robertson S, Bekker LG. Tuberculosis control has failed in South Africa-time to reappraise strategy. S Afr Med J 2011; 101: 111-114.